SurGenTec Gains FDA Clearance for OsteoFlo HydroFiber

SurGenTec OsteoFlo HydroFiber

SurGenTec received FDA 510(k) clearance to market OsteoFlo HydroFiber bone graft technology, a stand-alone solution equivalent to autograft for spine surgeries, including use in interbody fusion cages, disc spaces and posterolateral fusions.

OsteoFlo HydroFiber is slated for launch in early 2025.

The product leverages Web Interlace...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0